Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4016H | ISIN: US04272N1028 | Ticker-Symbol:
NASDAQ
28.03.25
20:43 Uhr
18,900 US-Dollar
+0,280
+1,50 %
1-Jahres-Chart
ARRIVENT BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
ARRIVENT BIOPHARMA INC 5-Tage-Chart

Aktuelle News zur ARRIVENT BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside1
20.03.B.Riley sets $37 target on ArriVent stock, initiates with Buy1
13.03.ArriVent BioPharma, Inc. - 8-K, Current Report1
07.03.H.C. Wainwright maintains Buy on ArriVent shares, $39 target1
ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln
03.03.Oppenheimer maintains AVBP Outperform rating, $39 price target1
03.03.ArriVent Biopharma, Inc. Full Year Loss Beats Estimates3
03.03.ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Full Year 2024 Financial Results105First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib...
► Artikel lesen
03.03.ArriVent BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
03.03.ArriVent BioPharma, Inc. - 8-K, Current Report-
03.03.ArriVent BioPharma, Inc. - 10-K, Annual Report-
17.02.ArriVent BioPharma, Inc. (NASDAQ:AVBP) Short Interest Up 9.1% in January1
23.01.Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim1
22.01.ArriVent Biopharma enters license agreement with Lepu Biopharma2
22.01.ArriVent continues to bulk out ADC pipeline, paying Lepu $47M for preclinical GI asset1
22.01.China's Lepu Soars on Granting US' ArriVent Global Rights to New Cancer Drug in USD1.2 Billion Deal1
22.01.ArriVent BioPharma, Inc.: ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers210Exclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst Investigational New Drug (IND) submission...
► Artikel lesen
22.01.ArriVent BioPharma, Inc. - 8-K, Current Report-
15.11.24ArriVent BioPharma GAAP EPS of -$0.61 beats by $0.112
14.11.24ArriVent BioPharma, Inc. - 10-Q, Quarterly Report-
14.11.24ArriVent BioPharma, Inc. - 8-K, Current Report-
Seite:  Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1